OGX-011
information and resources from the National Cancer Institute
NCI Thesaurus | OGX-011
A mixed-backbone antisense oligodeoxynucleotide with chemosensitizing properties. OGX-011 inhibits testosterone-repressed prostate message-2 (TRPM-2). Administration of OGX-011 abrogates the anti-apoptotic effect of TRPM-2, thereby sensitizing cells to chemotherapy and resulting in tumor cell death. TRPM-2 is an anti-apoptotic clusterin that is overexpressed by prostate cancer cells and is associated with chemoresistance. NCI Thesaurus | OGX-011
A mixed-backbone antisense oligodeoxynucleotide with chemosensitizing properties. OGX-011 inhibits testosterone-repressed prostate message-2 (TRPM-2). Administration of OGX-011 abrogates the anti-apoptotic effect of TRPM-2, thereby sensitizing cells to chemotherapy and resulting in tumor cell death. TRPM-2 is an anti-apoptotic clusterin that is overexpressed by prostate cancer cells and is associated with chemoresistance.
|
|
|
|
news articles
OncoGenex Initiates Fourth Phase 2 Clinical Trial of OGX-011 in ... Oct 25, 2005
PR Newswire (press release), Study to assess the ability of OGX-011 to enhance response to chemotherapy in breast cancer patients VANCOUVER, Oct. 25 /PRNewswire ...
OncoGenex Initiates Fourth Phase 2 Clinical Trial of OGX-011 in ... Oct 25, 2005
PharmaLive.com (press release), ...announced today that the first patient has been treated in a Phase 2 clinical trial of OGX-011 in combination with docetaxel in patients with advanced breast ...
Isis Pharmaceuticals Reports Financial Results and Highlights for ... Nov 8, 2005
PR Newswire (press release), 350 mg/week of ISIS 301012 for one month, achieved a median reduction of 60% in apoB-100 and a median reduction of 54% in LDL-C. OGX-011 * OncoGenex initiated ...
|
|
